It has recently been approved as single disease-modifying therapy in highly active relapsing-remitting MS (RRMS) for adult patients with high disease activity despite basic treatment (beta-interferon) and for treatment-naïve patients with rapidly evolving severe RRMS. The gene discussed is IFNB1; the disease is relapsing-remitting multiple sclerosis.